Plasma Resolvin D2 to Leukotriene B Ratio Is Reduced in Diabetic Patients with Ischemic Stroke and Related to Prognosis.

BACKGROUND

Diabetes mellitus (DM) aggravates symptoms and prognosis of acute ischemic stroke (AIS), and inflammation plays an important role therein. Resolvin D2 (RvD2) is one of the specialized pro-resolving mediators (SPMs), while leukotriene B (LTB) is a classic proinflammatory mediator. The ratio of RvD2 to LTB is an index of pro-resolving/proinflammatory balance. We aim to explore the role of RvD2/LTB ratio in ischemic stroke complicated with DM.

METHODS

The plasma levels of RvD2 and LTB were analyzed by enzyme immunoassay in stroke patients with DM (DM + AIS group) or without DM (nonDM+AIS group). Patients were followed up at 90 days after stroke onset, and modified Rankin Score (mRS) was assessed. The association of RvD2/LTB ratio with stroke severity and prognosis was also analyzed.

RESULTS

The plasma levels of RvD2 were positively correlated to LTB. The RvD2/LTB ratio in DM + AIS group was lower than that in the nonDM+AIS group. No correlation was found between the RvD2/LTB ratio and infarct size or NIHSS score. The RvD2/LTB ratio at baseline was significantly lower in the poor prognosis group (mRS ≥ 3) than that in the good prognosis group (mRS ≤ 2).

CONCLUSIONS

Our study indicated that the balance between pro-resolving and proinflammatory mediators was impaired by diabetes in ischemic stroke. The RvD2/LTB ratio may serve as a biomarker of prognosis for ischemic stroke.